基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
(18)F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描预测早期三阴性乳腺癌的肿瘤免疫微环境功能
英文原题：(18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer.
查看英文原题
(18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
SUVmax 可为 TNBC 患者提供有关 TIME 的代谢信息，并可能有助于制定治疗策略和预测新辅助化疗后的 pCR。
中文摘要
患者与方法
54例TNBC患者在新辅助化疗前接受FDG PET/CT检查，并对治疗前活检标本进行病理评估。采用免疫组化检测CD8、叉头框蛋白P3（FOXP3）、程序性细胞死亡蛋白1（PD-1）及其配体PD-L1表达，并分析包括TIL（肿瘤浸润淋巴细胞）分级在内的免疫因素与SUVmax或病理完全缓解（pCR）的关系。
结果
CD8、FOXP3、PD-1和PD-L1高表达患者分别为15例（27.8%）、39例（72.2%）、18例（33.3%）和26例（48.2%）。SUVmax与肿瘤大小、Ki-67标记指数及CD8/FOXP3比值显著相关。多元线性回归显示，肿瘤大小和CD8/FOXP3比值可预测SUVmax。17例患者（31.5%）达到pCR；TIL、CD8/FOXP3比值、PD-1和PD-L1均与pCR率显著相关。多变量分析显示，CD8/FOXP3比值是唯一独立的pCR预测因素。
结论
SUVmax可提供TNBC患者TIME的代谢信息，可能有助于制定治疗策略并预测新辅助化疗后的pCR。
展开英文摘要原文
PATIENTS AND METHODS
Fifty-four patients with TNBC underwent FDG PET/CT before neoadjuvant chemotherapy. Pretreatment biopsy specimens were pathologically evaluated. Expression statuses of CD8, forkhead box P3 (FOXP3), programmed cell death-1 (PD-1), and programmed cell death-ligand 1 (PD-L1) were assessed by immunohistochemistry. The relationships between immunological factors, including the tumor-infiltrating lymphocyte (TIL) grade and SUVmax or pathological complete response (pCR), were investigated.
RESULTS
CD8, FOXP3, PD-1, and PD-L1 were high in 15 (27.8%), 39 (72.2%), 18 (33.3%), and 26 (48.2%) patients, respectively. SUVmax was significantly correlated with tumor size, Ki-67 labeling index, and CD8/FOXP3 ratio. Multiple linear regression analysis indicated that tumor size and the CD8/FOXP3 ratio predicted SUVmax. Seventeen patients (31.5%) achieved a pCR; TILs, the CD8/FOXP3 ratio, PD-1, and PD-L1 were significantly correlated with pCR rate. Multivariate analysis indicated that the CD8/FOXP3 ratio was the only independent predictive factor for pCR.
CONCLUSION
SUVmax could provide metabolic information regarding TIME for TNBC patients and might be beneficial for formulating a treatment strategy and predicting pCR after neoadjuvant chemotherapy.
论文信息
- 作者
- Kimura Y、Sasada S、Emi A、Masumoto N、Kadoya T、Arihiro K、Okada M
- 第一作者单位
- Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.Japan
- 通讯作者单位
- Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; shsasada@hiroshima-u.ac.jp.Japan
- 期刊
- Anticancer research2023 Jan
- 原文标识
- PubMed 36585209 · DOI 10.21873/anticanres.16141